These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34092654)

  • 1. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
    Poewe W; Volc D; Seppi K; Medori R; Lührs P; Kutzelnigg A; Djamshidian A; Thun-Hohenstein C; Meissner WG; Rascol O; Schneeberger A; Staffler G; ; ; Poewe W; Seppi K; Djamshidian A; deMarzi R; Heim B; Mangesius S; Stolz R; Wachowicz K; Volc D; Thun-Hohenstein C; Riha C; Schneeberger A; Bürger V; Galabova G
    J Parkinsons Dis; 2021; 11(3):1079-1089. PubMed ID: 34092654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
    Meissner WG; Traon AP; Foubert-Samier A; Galabova G; Galitzky M; Kutzelnigg A; Laurens B; Lührs P; Medori R; Péran P; Sabatini U; Vergnet S; Volc D; Poewe W; Schneeberger A; Staffler G; Rascol O;
    Mov Disord; 2020 Nov; 35(11):1957-1965. PubMed ID: 32882100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
    Volc D; Poewe W; Kutzelnigg A; Lührs P; Thun-Hohenstein C; Schneeberger A; Galabova G; Majbour N; Vaikath N; El-Agnaf O; Winter D; Mihailovska E; Mairhofer A; Schwenke C; Staffler G; Medori R
    Lancet Neurol; 2020 Jul; 19(7):591-600. PubMed ID: 32562684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
    Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
    Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease.
    Smit JW; Basile P; Prato MK; Detalle L; Mathy FX; Schmidt A; Lalla M; Germani M; Domange C; Biere AL; Bani M; Carson S; Genius J
    Mov Disord; 2022 Oct; 37(10):2045-2056. PubMed ID: 35959805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
    Yu HJ; Thijssen E; van Brummelen E; van der Plas JL; Radanovic I; Moerland M; Hsieh E; Groeneveld GJ; Dodart JC
    Mov Disord; 2022 Jul; 37(7):1416-1424. PubMed ID: 35426173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase I Trial of the α-Synuclein Antibody Lu AF82422.
    Buur L; Wiedemann J; Larsen F; Ben Alaya-Fourati F; Kallunki P; Ditlevsen DK; Sørensen MH; Meulien D
    Mov Disord; 2024 Jun; 39(6):936-944. PubMed ID: 38494847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and effectiveness of α-synuclein immunotherapy vs. placebo for the treatment of Parkinson's disease: a systematic review and meta-analysis.
    Hu F; Zhang S; Wang C; Zhou H; Shi H
    Ann Palliat Med; 2022 Dec; 11(12):3764-3774. PubMed ID: 36636001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials.
    Antonini A; Bravi D; Sandre M; Bubacco L
    Expert Opin Investig Drugs; 2020 Jul; 29(7):685-695. PubMed ID: 32419521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
    Wang Z; Gao G; Duan C; Yang H
    Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.
    Eijsvogel P; Misra P; Concha-Marambio L; Boyd JD; Ding S; Fedor L; Hsieh YT; Sun YS; Vroom MM; Farris CM; Ma Y; de Kam ML; Radanovic I; Vissers MFJM; Mirski D; Shareghi G; Shahnawaz M; Singer W; Kremer P; Groeneveld GJ; Yu HJ; Dodart JC
    Nat Med; 2024 Jun; ():. PubMed ID: 38902546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
    Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
    Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.
    Schenk DB; Koller M; Ness DK; Griffith SG; Grundman M; Zago W; Soto J; Atiee G; Ostrowitzki S; Kinney GG
    Mov Disord; 2017 Feb; 32(2):211-218. PubMed ID: 27886407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Parkinson's disease: Current status and future directions.
    Chatterjee D; Kordower JH
    Neurobiol Dis; 2019 Dec; 132():104587. PubMed ID: 31454546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
    Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
    PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
    Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
    Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.